AstraZeneca Back Participating Organisations List>

AstraZeneca is a science-based global biopharmaceutical company focused on the development, production and marketing of prescription drugs, with a focus on the three core diseases of cancer, cardiovascular and metabolic diseases, and respiratory. At the same time, AstraZeneca is also selectively active in the fields of autoimmune, neuroscience and infection. With a presence in more than 100 countries, AstraZeneca's innovative medicines benefit millions of patients worldwide. Since entering China in 1993, AstraZeneca has adhered to the supremacy of science and innovation to meet China's growing health needs and achieve the grand vision of “exploiting and innovating, benefiting patients and becoming China's most trusted medical partner”. AstraZeneca's China headquarters is located in Shanghai and has more than 10,000 employees across the country. The company has invested in Wuxi and Taizhou to build a production base and established a China logistics center in Wuxi. In China, AstraZeneca's business focus is on the treatment areas most needed by Chinese patients, including respiratory, cardiovascular, metabolic, oncological, digestive, and kidney diseases. In 2017, the AstraZeneca China Business Innovation Center was launched in Wuxi to explore innovative, integrated IoT diagnosis and treatment solutions for healthy IoT. In the same year, AstraZeneca and SDIC Innovation jointly established Dizhe (Jiangsu) Pharmaceutical Co., Ltd. to accelerate the pace of research and development of new local medicines for the benefit of Chinese patients.